Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Short Interest Down 18.0% in March

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) was the recipient of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 2,570,623 shares, a decrease of 18.0% from the February 26th total of 3,133,929 shares. Based on an average daily volume of 3 shares, the days-to-cover ratio is presently 856,874.3 days.

Neuren Pharmaceuticals Price Performance

Shares of NURPF opened at C$8.22 on Wednesday. Neuren Pharmaceuticals has a 52-week low of C$6.60 and a 52-week high of C$14.80. The firm’s fifty day moving average is C$9.62 and its two-hundred day moving average is C$11.66.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.